4
Participants
Start Date
September 26, 2016
Primary Completion Date
March 16, 2017
Study Completion Date
March 16, 2017
Exenatide
Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate \>=6 hours apart)
Albiglutide
Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
GSK Investigational Site, Louisville
GSK Investigational Site, Dallas
Lead Sponsor
Wake Forrest Baptist Health
UNKNOWN
GlaxoSmithKline
INDUSTRY